Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis

Abstract Background LIGHT (oLaparib In HRD-Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD-positive non-BRCAm, and HRD-negative. At the primary analysis, olaparib treatment demonstrated activity across all… Continue reading Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis

Quasispecies theory and emerging viruses: challenges and applications

Abstract Quasispecies theory revolutionized our understanding of viral evolution by describing viruses as dynamic populations of genetically diverse variants constantly adapting. This article explores the theory’s role in virus-host interactions, including immune evasion, drug resistance, and viral emergence. We review the original model, recent advances, and key virus dynamics needing incorporation into quasispecies theory. We… Continue reading Quasispecies theory and emerging viruses: challenges and applications

347 Highly multiplexed engineering of immune effector cells for advanced cancer therapies

Background To address the challenges of advanced cancers using cellular immunotherapy, it will likely require cutting-edge, multiplex genome engineered immune effector cells. Fortuitously, the development of ‘digital editors’, such as base editors (BEs), have enabled multiplex editing without induction of double strand breaks (DSBs) or need for a DNA donor to install gain- or loss-of-function… Continue reading 347 Highly multiplexed engineering of immune effector cells for advanced cancer therapies

1392 Immune infiltration is associated with improved survival in primary, advanced-stage p53-abnormal endometrial carcinoma

Background Our group and others previously demonstrated that endometrial carcinoma (EC) is comprised of four molecular subtypes that are biologically distinct, diagnostically reproducible, and highly significantly prognostic. Among these subtypes, p53 abnormal (p53abn) EC is by far the deadliest, with over 50% of patients succumbing to disease within 5 years. Recent clinical trials demonstrated that… Continue reading 1392 Immune infiltration is associated with improved survival in primary, advanced-stage p53-abnormal endometrial carcinoma